Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift

Nature Reviews Clinical Oncology, Published online: 26 January 2024; doi:10.1038/s41571-024-00861-7Durable responses with first-line platinum-based chemotherapy for advanced-stage urothelial carcinoma are rare, and patient outcomes are poor. Recently, CheckMate 901 became the first phase III trial to establish a significant overall survival benefit from a combined chemoimmunotherapy approach in this disease setting. Herein, we discuss key findings from CheckMate 901 and their implications in the context of a rapidly evolving treatment landscape.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research